[go: up one dir, main page]

AR092104A1 - LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) - Google Patents

LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)

Info

Publication number
AR092104A1
AR092104A1 ARP130102859A ARP130102859A AR092104A1 AR 092104 A1 AR092104 A1 AR 092104A1 AR P130102859 A ARP130102859 A AR P130102859A AR P130102859 A ARP130102859 A AR P130102859A AR 092104 A1 AR092104 A1 AR 092104A1
Authority
AR
Argentina
Prior art keywords
laquinimod
gaba
treatment
disorders mediated
aminobutiric acid
Prior art date
Application number
ARP130102859A
Other languages
English (en)
Inventor
Martino Gianvito
Centonze Diego
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR092104A1 publication Critical patent/AR092104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para tratar un sujeto que padece un trastorno relacionado con el GABA, que comprende administrarle periódicamente al sujeto una cantidad eficaz para efectuar el tratamiento de laquinimod o de una sal farmacéuticamente aceptable de éste. Reivindicación 31: Una composición farmacéutica que comprende una cantidad de laquinimod, caracterizada porque es eficaz para tratar un sujeto humano que padece un trastorno relacionado con el GABA.
ARP130102859A 2012-08-13 2013-08-12 LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) AR092104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261682576P 2012-08-13 2012-08-13

Publications (1)

Publication Number Publication Date
AR092104A1 true AR092104A1 (es) 2015-03-25

Family

ID=50066660

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102859A AR092104A1 (es) 2012-08-13 2013-08-12 LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)

Country Status (8)

Country Link
US (1) US9161936B2 (es)
EP (1) EP2882438A4 (es)
AR (1) AR092104A1 (es)
CA (1) CA2881973A1 (es)
IL (1) IL237042A0 (es)
MX (1) MX2015001888A (es)
TW (1) TW201410244A (es)
WO (1) WO2014028397A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP1797109B1 (en) 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
AU2006204699B2 (en) 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
PT1937642E (pt) 2005-10-19 2014-11-25 Teva Pharma Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos
KR20140091778A (ko) * 2006-06-12 2014-07-22 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP1886996A1 (en) 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
WO2008152444A2 (en) * 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
JP2010513518A (ja) 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
US8343996B2 (en) 2008-11-13 2013-01-01 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
SI2442651T1 (sl) 2009-06-19 2015-10-30 Teva Pharmaceutical Industries Ltd. Zdravljenje multiple skleroze z lakvinimodom
KR20160148050A (ko) 2009-07-30 2016-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
US9585878B2 (en) * 2009-08-10 2017-03-07 Teva Pharmaceutical Industries, Ltd. Treatment of BDNF-related disorders using laquinimod
KR20160129093A (ko) 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
PH12012501740A1 (en) 2010-03-03 2012-11-12 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
PH12012501741A1 (en) 2010-03-03 2012-11-12 Teva Pharma Treatment of lupus arthritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
WO2012062925A2 (en) 2010-11-11 2012-05-18 Akron Molecules Gmbh Compounds and methods for treating pain
SG10201509831XA (en) 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2014521659A (ja) 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
CN103781354A (zh) 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201804997A (zh) 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
UY34896A (es) 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
TW201410243A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2015533163A (ja) 2012-10-12 2015-11-19 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症における視床損傷を低減するためのラキニモド
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
CA2900977A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof

Also Published As

Publication number Publication date
IL237042A0 (en) 2015-03-31
TW201410244A (zh) 2014-03-16
EP2882438A2 (en) 2015-06-17
EP2882438A4 (en) 2016-08-03
WO2014028397A2 (en) 2014-02-20
WO2014028397A3 (en) 2015-07-16
US9161936B2 (en) 2015-10-20
US20140045886A1 (en) 2014-02-13
CA2881973A1 (en) 2014-02-20
MX2015001888A (es) 2015-05-07

Similar Documents

Publication Publication Date Title
MX391624B (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
BR112015022197A2 (pt) tratamento de cataplexia
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112015006341A2 (pt) compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201490495A1 (ru) Новые легкоразрушающиеся ингибиторы rock
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
MX359259B (es) Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс

Legal Events

Date Code Title Description
FB Suspension of granting procedure